Skip to main content
SpringerLink
Log in

Bisphosphonate in der Osteoporosetherapie

Standards und Perspektiven

Bisphosphonates in osteoporosis therapy

Standards and perspectives

  • Leitthema
  • Published:
Der Orthopäde Aims and scope Submit manuscript

Zusammenfassung

Die Substanzgruppe der Bisphosphonate setzt sich aus potenten Inhibitoren der Knochenresorption zusammen, welche eine präverierte Therapie für die Prävention und für die Therapie der Osteoporose darstellt. Zahllose klinische Studien haben eine konsistente Reduktion des Risikos für vertebrale Frakturen unter dem Einsatz der Bisphosphonate erbracht. Des Weiteren konnte klar eine Reduktion des Hüftfrakturrisikos und des Risikos für andere nicht-vertebrale Frakturen erbracht werden.

Die Bisphosphonate werden nach ihrer Potenz und der chemischen Struktur in 3 Generationen eingeteilt. Insgesamt als Substanzgruppe wird dies sehr gut vertragen und Toxizitäten bei richtiger Anwendung sind gering. Alternative Dosierungen, z. B. monatlich, 3-monatlich oder jährlich als orale oder i.v.-Gabe werden wahrscheinlich die Compliance der Patienten verbessern. Des Weiteren konnte in den klinischen Studien die Sicherheit und die Effektivität der Bisphosphonate über einen Zeitraum von 3-7 Jahren nachgewiesen werden.

Abstract

Bisphosphonates are potent inhibitors of bone resorption and approved agents for both the prevention and treatment of osteoporosis. Many clinical studies have shown a consistent reduction in the risk of vertebral fractures with the use of these drugs, while others have shown a clear reduction in the risk of hip and other non-vertebral fractures.

The bisphosphonates are divided into three generations based on their potency and chemical structure. In general, as a substance group they are well tolerated and, when applied correctly, the toxicity is low. Alternative dosages, e.g. monthly, three times a month or yearly as an oral drug or i.v. would probably improve patient compliance. Clinical studies have also shown the safety and effectiveness of bisphosphonates over a period of 3–7 years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Armamento-Villareal R, Napoli N, Panwar V, Novack D (2006) Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 355: 2048–2050

    Article  Google Scholar 

  2. Black D, Schwartz A, Ensrud K et al. (2004) A 5 year randomized trial of the long-term efficary and safety of alendronate: The FIT Long-term Extension (FLEX). J Bone Miner Metab 19(Suppl 1): 45

    Google Scholar 

  3. Black DM, Thompson DE, Bauer DC et al. (2000) Fracture risk reduction with alendronate in women with osteoporosis: theFracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85: 4118–4124

    Article  PubMed  Google Scholar 

  4. Bone HG, Hosking D, Devogelaer JP et al. (2004) Ten years‘ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189–1199

    Article  PubMed  Google Scholar 

  5. Boonen S, Orwoll ES, Wenderoth D et al. (2006) Risedronate is effective in men with osteoporosis regardless of baseline testosterone level and prevalent vertebral fracture status. ASMBR 2006: 346

    Google Scholar 

  6. Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP (2001) Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion and infusion given once every 3 months, and calcium alone. J Bone Miner Res 16: 104–112

    Article  PubMed  Google Scholar 

  7. Chestnut III CH, Skag A, Christiansen C et al. (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19: 1241–1249

    Article  PubMed  Google Scholar 

  8. Chesnut III CH, Ettinger MP, Miller PD et al. (2005) Ibandronate producessignificant, similar antifractureefficacy in North American and European women: new clinicalfindings from bone. Curr Med Res Opin 2005: 21391–2401

    Google Scholar 

  9. Cohen S, Levy RM, Keller M et al. (1999) Risedronates therapy prevents corticosteroid-induced osteoporosis bone loss. Arthritis Rheum 42: 2309–2318

    Article  PubMed  Google Scholar 

  10. Cranney A, Guyatt G, Krolickin et al. (2001) A metaanalysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporosis Research Advisory Group. Osteoporos Int 12: 140–151

    Article  PubMed  Google Scholar 

  11. Delmas PD, Adami S, Strugala C et al. (2006) Intravenous Ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study. Art Rheum 54: 1838–1846

    Article  Google Scholar 

  12. Eastell R, Barton I, Hannon R et al. (2001) Antifracture efficacy of risedronate prediction by change in bone resorption markers. J Bone Miner Res 16: 163

    Google Scholar 

  13. Felsenberg D, Hoffmeister B, Amling M et al. (2006) Kiefernekrosen nach hoch dosierterBisphosphonattherapie. Dtsch Arztebl A 103: 3078–3080

    Google Scholar 

  14. Felsenberg D, Miller PD, Armbrecht G et al. (2005) Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone 37: 651–654

    Article  PubMed  Google Scholar 

  15. Fleisch H (1998) Bisphosphonates: mechanisms of action. Endo Rev 19: 80–100

    Article  Google Scholar 

  16. Harris ST, Watts NB, Genant HK et al. (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282: 1344–1352

    Article  PubMed  Google Scholar 

  17. Heijckmann AC, Juttman JR, Wolffenbuttel BH (2002) Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis. Neth J Med 60: 315–319

    PubMed  Google Scholar 

  18. Mashiba T, Turner CH, Hirano T et al. (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28: 524–531

    Article  PubMed  Google Scholar 

  19. McCloskey E, Selby P, deTakats D et al. (2001) Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis. Bone 28: 310–315

    Article  PubMed  Google Scholar 

  20. McClung M, Geusens P, Miller P et al. (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344: 333–340

    Article  PubMed  Google Scholar 

  21. Mellstrom DD, Sorensen OH, Goemaere S et al. (2004) Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75: 462–468

    Article  PubMed  Google Scholar 

  22. Miller PD, Watts NB, Licata AA et al. (1997) Cyclic etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. Am J Med 103: 468–476

    Article  PubMed  Google Scholar 

  23. Miller PD, McClung MR, Macovei L et al. (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20: 1315–1322

    Article  PubMed  Google Scholar 

  24. Orwoll E, Ettinger M, Weiss S et al. (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343: 604–610

    Article  PubMed  Google Scholar 

  25. Pols HA, Felsenberg D, Hanley DA et al. (1999) Multinational, placebo-controlled, randomized trial of the effects ofalendronate on bone density and fracture risk in postmenopausal women with lowbone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9: 461–468

    Article  PubMed  Google Scholar 

  26. Recker R, Ensrud K, Diem S et al. (2004) Normal Bone histomorphometry and 3D microarchitecture after 10 years alendronate treatment of postmenopausal women. J Bone Miner Metab 19(Suppl 1): 45

    Google Scholar 

  27. Reginster J, Minne HW, Sorensen OH et al. (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with estabilished postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11: 83–91

    Article  PubMed  Google Scholar 

  28. Reginster JY, Lecart MP, Deroisy R, et al. (1989) Prevention of postmenopausal bone loss by tiludronate. Lancet 2: 1469–1471

    Article  PubMed  Google Scholar 

  29. ReginsterJY, Adami S, Lakatos P et al. (2006) Efficacy and tolerability of once-monthly oralibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis 65: 654–661

    Article  PubMed  Google Scholar 

  30. Reid DM, Hughes RA, Laan RF et al. (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-indurced osteoporosis in men and women: a randomized trial. J Bone Miner Res 15: 1006–1123

    Article  PubMed  Google Scholar 

  31. Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F (2003) Intermittent intravenous ibandronate injections reduce vertebral fracture risk in cortcosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 14: 801–807

    Article  PubMed  Google Scholar 

  32. Rogers MJ, Russell RGG (1999) Bisphosphonates: from the labortory to the clinic and back again. Bone 25: 97–106

    Article  PubMed  Google Scholar 

  33. Roux C, Seeman E, Eastell R et al. (2004) Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 20: 433–439

    Article  PubMed  Google Scholar 

  34. Saag KG, Emkey R, Schnitzer TJ et al. (1998) Alendronate fort he prevention and treatment of glucocorticoid-induced osteoporosis. N Eng J Med 339: 292–299

    Article  Google Scholar 

  35. Silverman SL, Watts NB, Delmas PD et al. (2006) Effectiveness of bisphosphonates on nonvertebral and hipfractures in the first year of therapy: The risedronateand alendronate (REAL) cohort study. Osteoporos Int DOI 10.1007/s00198–006–0274

    Google Scholar 

  36. Storm T, Kollerup G, Thamsborg G et al. (1996) Five years of clinical experience with intermittent cyclic etidronate for postmenopausal osteoporosis. J Rheumatol 23: 1560–1564

    PubMed  Google Scholar 

  37. Thiebaud D, Burckhardt P, Kriegbaum H et al. (1997) Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103: 298–307

    Article  PubMed  Google Scholar 

  38. Van Beek ER, Lowik CW. Papapoulos SE (2002) Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone 30: 64–70

    Article  PubMed  Google Scholar 

  39. van Staa TP, Abenhaim L, Cooper C (1998) Use of cyclic etidronate and prevention of nonvertebral fractures. Br J Rheumatol 37: 87–94

    Article  PubMed  Google Scholar 

  40. Vasikaran SD (2001) Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem 38: 608–623

    Article  PubMed  Google Scholar 

  41. Vis M, Bultink L, Dijkmans B, Lems W (2004) The effect of oral alendronate versus intravenous pamindronate on bone mineral density in patients with osteoporosis. J Bone Miner Metab 19(Suppl 1): 311

    Google Scholar 

  42. Watts N, Adami S, Chesnut CH 3rd et al. (2001) Risedronate reduces the risk of clinical vertebral fractures in just 6 months. J Bone Miner Res 16: 407

    Google Scholar 

  43. Watts NB (2001) Treatment of osteoporosis with bisphosphonates. Rheum Dis Clin North Am 27: 197–214

    Article  PubMed  Google Scholar 

  44. Whyte MP, Wenkert D, Clements KL et al. (2003) Bisphosphonate-induced osteopetrosis. N Engl J Med 349: 457–463

    Article  PubMed  Google Scholar 

  45. Wimalawansa SJ (1998) A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 104: 219–226

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor hat einen Interessenkonflikt, da er für die Firmen der angegebenen Produkte im Rahmen von klinischen Studien und in wissenschaftlichen Beiräten tätig war oder ist sowie Vorträge über die Produkte gehalten hat.

Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

  1. Ortopädische Praxis am Fürstenhof, Frankfurt, Deutschland

    S. Reinsdorf

  2. Orthopädische Universitätsklinik Frankfurt, Stiftung Friedrichsheim, Marienburgstraße 2, 60528, Frankfurt, Deutschland

    B. Habermann, K. Hochmuth &  A.A. Kurth

Authors
  1. S. Reinsdorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Habermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Hochmuth
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A.A. Kurth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A.A. Kurth.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reinsdorf, S., Habermann, B., Hochmuth, K. et al. Bisphosphonate in der Osteoporosetherapie. Orthopäde 36, 110–117 (2007). https://doi.org/10.1007/s00132-006-1035-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00132-006-1035-6

Schlüsselwörter

Keywords

Search

Navigation